Florian Voß

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies

Cell cycle proteins as promising targets in cancer therapy

New treatment for acute myelogenous leukemia

Efficacy and Mechanism of Action of Volasertib, a Potent and Selective Inhibitor of Polo-Like Kinases, in Preclinical Models of Acute Myeloid Leukemia

A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer

An Integrated View of Insulin Resistance and Endothelial Dysfunction

Kynurenine is an endothelium-derived relaxing factor produced during inflammation

Targeting apoptosis in cancer therapy

Equine Metabolic Syndrome

Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications

Inducible nitric oxide synthase: Good or bad?

Differential Regulation of Lipoprotein and Hepatitis C Virus Secretion by Rab1b

Hepatitis C Virus: 30 Years after Its Discovery

The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets

Understanding the hepatitis C virus life cycle paves the way for highly effective therapies

Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond

Taming a beast: lessons from the domestication of hepatitis C virus

Kaempferol inhibits VEGF expression and in vitro angiogenesis through a novel ERK-NFκB-cMyc-p21 pathway

Acute Myeloid Leukemia

Capturing Magnesium Ions via Microfluidic Hydrogel Microspheres for Promoting Cancellous Bone Regeneration

Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1

Characterization of nonprimate hepacivirus and construction of a functional molecular clone

Initial testing (stage 1) of the polo‐like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program

Identification of AP80978, a Novel Small-Molecule Inhibitor of Hepatitis C Virus Replication That Targets NS4B

How I treat refractory and early relapsed acute myeloid leukemia

Green Tea Polyphenol Epigallocatechin Gallate Reduces Endothelin-1 Expression and Secretion in Vascular Endothelial Cells: Roles for AMP-Activated Protein Kinase, Akt, and FOXO1

Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells

Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics

Kaempferol: A Key Emphasis to Its Anticancer Potential

Regulatory T cells expressing abundant CTLA‐4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer

The Vascular Endothelium and Human Diseases

An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

Lack of Endothelial Nitric Oxide Synthase Promotes Endothelin-Induced Hypertension

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies

Myc Regulates Embryonic Vascular Permeability and Remodeling

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment

1227 AN ANALYSIS OF RESPONSE RATES BY FIBROSIS STAGE IN PATIENTS TREATED WITH FALDAPREVIR, BI 207127 AND RIBAVIRIN IN THE SOUND-C2 STUDY

A phase I dose-escalation study of the polo-like kinase 1 inhibitor volasertib (BI 6727) with two different dosing schedules in patients with advanced solid malignancies.

Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML